Dr. Tingyan Shi 史庭燕
Chief Physician, Associate Professor
Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of benign and malignant gynecologic tumors, including endometrial, cervical, and ovarian cancers. Comprehensive care for advanced and recurrent cases, especially recurrent ovarian cancer. Genetic counseling, management of cervical and endometrial lesions, and tumor prevention.
Dr. Shi is Deputy Director of the Gynecologic Oncology Department at Zhongshan Hospital, Fudan University. Holding a PhD from Fudan University and having completed postdoctoral work at the University of Oxford, Dr. Shi focuses on clinical and translational research in gynecologic tumors. Dr. Shi has led National Natural Science Foundation projects and published over 20 SCI articles.
Professional roles
- Chair, Integrated Traditional Chinese and Western Medicine Cervical Cancer Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Shi Tingyan). Papers usually list the name as Tingyan Shi or Shi T.
Selected publications
50 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Chin Med J (Engl), 2026 (senior author): g BRCA1 and g BRCA2 mutations in specific different domains affect ovarian cancer prognosis: A multicenter retrospective study. PubMed 40709810
- J Gynecol Oncol, 2025 (first author): Optimal timing of primary debulking surgery in advanced ovarian cancer: insights from the TRUST trial. PubMed 40878400
- Chin Med J (Engl), 2024 (first author): Shanghai Gynecologic Oncology Group's consensus on the academic and industry's clinical trial types. PubMed 38654409
- J Gynecol Oncol, 2022 (first author): Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study. PubMed 35775688
- Lancet Oncol, 2021 (first author): Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. PubMed 33705695
- J Gynecol Oncol, 2020 (first author): A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study. PubMed 32319233
- Br J Cancer, 2019 (first author): Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study. PubMed 31383985
- Br J Cancer, 2018 (first author): Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial. PubMed 29899395
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion